← Leaderboards
Scott E. Strome
Mayo Clinic Coll Of Medicine, Rochester
$1,734,614
Attributed
$1,734,614
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $354.4K · FY2005–11$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$1,734,614 · 6
By mechanism
R01$1,129,936 · 2
K23$580,450 · 1
M01$24,228 · 3
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- James R Cerhan$31,221,407
- Peter Johnson Wettstein$2,963,460
- Alex A Adjei$13,436,633
- Lisa Allyn Boardman$12,819,757
- Neil E Kay$14,251,394
Others in their field
Top investigators on “T Lymphocyte”
- Barton F Haynes · Duke University$408,040,925
- Lawrence Corey · Fred Hutchinson Cancer Center$299,247,526
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$157,640,776
- Dan H. Barouch · Fred Hutchinson Cancer Center$139,062,963
- James Dennis Neaton · Northwestern University$107,288,548
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$83,920,398
Research focus
T LymphocyteHead /Neck NeoplasmTumor AntigensNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer VaccineSquamous Cell CarcinomaHuman SubjectClinical ResearchNonhuman Therapy EvaluationDisease /Disorder ModelDendritic CellsMelanomaMetastasisPassive ImmunizationLaboratory MouseHeat Shock ProteinsVaccine DevelopmentResearch PersonnelResponseMalignant NeoplasmsAntigensImmunotherapyColony Stimulating FactorDrug Screening /Evaluation
Grant awards (13)
LIGHT co-stimulatory therapy on GVHD and GVL$337,500
R01 · FY2011 · HL · contact PI
CLINICAL TRIAL: MAGE-A3/HPV16 PEPTIDE IMMUNOTHERAPEUTIC VACCINES FOR SQUAMOUS CE$11,581
M01 · FY2008 · RR · contact PI
0524GCC$10,171
M01 · FY2007 · RR · contact PI
MAGE-A3/HPV 16 Peptide Vaccines for Head and Neck Cancer$346,115
R01 · FY2006 · DE · contact PI
MAGE-A3/HPV 16 PEPTIDE VACCINES FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK$2,476
M01 · FY2006 · RR · contact PI
MAGE-A3/HPV 16 Peptide Vaccines for Head and Neck Cancer$354,445
R01 · FY2005 · DE
METHODS TO ENHANCE IMMUNOTHERAPY OF HEAD AND NECK CANCER$100,498
K23 · FY2004 · DE
MAGE-A3/HPV 16 Peptide Vaccines for Head and Neck Cancer$91,875
R01 · FY2004 · DE
MAGE-A3/HPV 16 Peptide Vaccines for Head and Neck Cancer$1
R01 · FY2004 · DE
METHODS TO ENHANCE IMMUNOTHERAPY OF HEAD AND NECK CANCER$119,988
K23 · FY2003 · DE
METHODS TO ENHANCE IMMUNOTHERAPY OF HEAD AND NECK CANCER$119,988
K23 · FY2002 · DE
METHODS TO ENHANCE IMMUNOTHERAPY OF HEAD AND NECK CANCER$119,988
K23 · FY2001 · DE
METHODS TO ENHANCE IMMUNOTHERAPY OF HEAD AND NECK CANCER$119,988
K23 · FY2000 · DE